Best-Selling Specialty Drug List Tops SPT Week in Review

5. Class Action Lawsuit Filed Against AbbVie, Biosimilar Manufacturers

Lawsuit alleges that patients paid artificially high prices for brand-name Humira, and that they were deprived of the benefits of early, robust competition from biosimilars as a result of wrongful conduct. Read more.
 

4. Solriamfetol Approved for Excessive Daytime Sleepiness from Narcolepsy, Obstructive Sleep Apnea

Solriamfetol (Sunosi, Jazz Pharmaceuticals) is the first dual-acting dopamine and norepinephrine reuptake inhibitor approved for this indication. Read more.
 

3. Ramucirumab, Erlotinib Combo Delays Disease Progression in NSCLC Trial

The phase 3 RELAY trial met its primary endpoint in significantly improving progression-free survival in metastatic EGFR-mutated non-small cell lung cancer. Read more.

2. FDA OKs First Immunotherapy Regimen for Extensive Small Cell Lung Cancer

Extensive-stage small cell lung cancer is a difficult-to-treat, aggressive type of cancer with limited treatment options. Read more.

1. Top 5 Best-Selling Specialty Drugs from 2018

Specialty therapies for autoimmune diseases and cancer topped the list of biggest-selling drugs for 2018. Read more.




Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Top news of the week from Specialty Pharmacy Times.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Cohesion among key stakeholders, which will lead to an evolution in care, is clearly on the rise, and the growth of those relationships will only benefit patients in the end.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$